» Articles » PMID: 30417363

Fifteen Hub Genes Associated with Progression and Prognosis of Clear Cell Renal Cell Carcinoma Identified by Coexpression Analysis

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2018 Nov 13
PMID 30417363
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Renal cell carcinoma (RCC) is the most common type of renal tumor, and the clear cell renal cell carcinoma (ccRCC) is the most frequent subtype. In this study, our aim is to identify potential biomarkers that could effectively predict the prognosis and progression of ccRCC. First, we used The Cancer Genome Atlas (TCGA) RNA-sequencing (RNA-seq) data of ccRCC to identify 2370 differentially expressed genes (DEGs). Second, the DEGs were used to construct a coexpression network by weighted gene coexpression network analysis (WGCNA). Moreover, we identified the yellow module, which was strongly related to the histologic grade and pathological stage of ccRCC. Then, the functional annotation of the yellow module and single-samples gene-set enrichment analysis of DEGs were performed and mainly enriched in cell cycle. Subsequently, 18 candidate hub genes were screened through WGCNA and protein-protein interaction (PPI) network analysis. After verification of TCGA's ccRCC data set, Gene Expression Omnibus (GEO) data set (GSE73731) and tissue validation, we finally identified 15 hub genes that can actually predict the progression of ccRCC. In addition, by using survival analysis, we found that patients of ccRCC with high expression of each hub gene were more likely to have poor prognosis than those with low expression. The receiver operating characteristic curve showed that each hub gene could effectively distinguish between localized and advanced ccRCC. In summary, our study indicates that 15 hub genes have great predictive value for the prognosis and progression of ccRCC, and may contribute to the exploration of the pathogenesis of ccRCC.

Citing Articles

Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.

Meng J, Jiang A, Lu X, Gu D, Ge Q, Bai S Imeta. 2024; 2(4):e147.

PMID: 38868222 PMC: 10989995. DOI: 10.1002/imt2.147.


Prognostic and therapeutic implications of iron-related cell death pathways in acute myeloid leukemia.

Li T, Lin T, Zhu J, Zhou M, Fan S, Zhou H Front Oncol. 2023; 13:1222098.

PMID: 37736548 PMC: 10509477. DOI: 10.3389/fonc.2023.1222098.


Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma.

Zhang Z, Tang Y, Li L, Yang W, Xu Y, Zhou J J Immunol Res. 2022; 2022:4946197.

PMID: 36313180 PMC: 9606837. DOI: 10.1155/2022/4946197.


Screening of Prognostic Markers for Hepatocellular Carcinoma Patients Based on Multichip Combined Analysis.

Dong Y, Miao Q, Li D Comput Math Methods Med. 2022; 2022:6881600.

PMID: 35872941 PMC: 9303125. DOI: 10.1155/2022/6881600.


The Hippo Pathway Effector Transcriptional Co-activator With PDZ-Binding Motif Correlates With Clinical Prognosis and Immune Infiltration in Colorectal Cancer.

Wang Y, Nie H, Li H, Liao Z, Yang X, He X Front Med (Lausanne). 2022; 9:888093.

PMID: 35865173 PMC: 9295930. DOI: 10.3389/fmed.2022.888093.